as well as a fixed-dose combination with Roche's lead incretin asset CT-388. Get top local stories in Connecticut delivered to you every morning. Sign up for NBC Connecticut's News Headlines ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (ZLDPF).

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Why it matters: Roche entered the obesity landscape with the $2.7 billion acquisition of Carmot in early 2024, giving the firm access to development-stage candidates, including CT-388 and oral ...

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate. Per the terms of the agreement, both companies will ...

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.

Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its CT-388 medicine combined with Zealand Pharma's petrelintide. The Swiss ...